| 2023-03-28 | +0.45 % |
- Martine van Vugt has been appointed as Chief Strategy Officer at Genmab, effective March 29, 2023, and her promotion has contributed to the successful management of strategic collaborations, including the partnership with AbbVie, leading to an increase in stock for AbbVie.
- Abbvie (ABBV) stock went up 0.45% due to the biopharma company's pipeline of more than 80 programs, dozens of drugs on the market, and expectations of revenue growth from its immunology medicines, Rinvoq and Skyrizi, and aesthetic portfolio, as well as the potential approval of new indications for its existing medicines, although its high dividend payout ratio and drug pricing practices are potential risks.
- The Motley Fool reports that AbbVie's (ABBV) stock went up by 0.45% following its position as the top-weighted stock in the Schwab U.S. Dividend ETF (SCHD), which offers investors strong dividend growth, share appreciation potential, and a solid yield.
|
| 2023-03-27 | -0.3 % |
|
| 2023-03-23 | +1.06 % |
|
| 2023-03-22 | -1.98 % |
|
| 2023-03-21 | +0.42 % |
|
| 2023-03-16 | +0.8 % |
|
| 2023-03-15 | +0.14 % |
- Abbvie (ABBV) stock went slightly up (0.14%) after the company announced the launch of a new documentary film, "Under My Skin: Untold Stories of Life with Eczema," which debuted at South by Southwest 2023 in Austin, Texas, hoping to shed some light on the impact of eczema through the lens of people living with the disease while also highlighting the resilient and supportive spirit within the eczema community.
- Halozyme Therapeutics has provided an update on a decision by the Opposition Division of the European Patent Office regarding one of the Janssen Biotech co-formulation patents for DARZALEX SC, stating that it expects no impact on US and European royalty revenues from DARZALEX FASPRO and SC through at least 2030, while Abbvie stock goes up by 0.14%.
- AbbVie (ABBV) stock went up by 0.14% last night, and the article discusses trichloroethylene (TCE), a common environmental contaminant that is little recognized for its likely role in contributing to the rise of Parkinson's disease.
- The stock of AbbVie (ABBV) went up by 0.14% last night following an announcement by Sosei Group Corporation, a biopharmaceutical company, that it has changed the market on which its shares are listed on the Tokyo Stock Exchange to the Prime Market segment, which is expected to deepen and broaden its shareholder base and improve its ability to attract diverse institutional investors, both domestic and international.
- The US Centers for Medicare and Medicaid Services announced that they will select the Medicare program's 10 costliest prescription medicines for negotiating price cuts to be effective from 2026 which is likely to include big-selling drugs made by Bristol Myers Squibb, Pfizer, and AbbVie, among others, leading to a possible rise in Abbvie(ABBV) stock.
|
| 2023-03-14 | +1.25 % |
|
| 2023-03-13 | +1.5 % |
|
| 2023-03-10 | +1.6 % |
|
| 2023-03-09 | -1.5 % |
- Caribou Biosciences announced its financial results for Q4 and full year 2022, highlighting progress in its pipeline, including CB-010 and CB-011 therapies in clinical trials, as well as plans to submit an IND for CB-012, but AbbVie's licensing and collaboration revenue from Caribou agreements saw an increase for the year, though ABBV stock fell by 1.5% on the day.
- AbbVie's (ABBV) stock went down by 1.5% last night despite Caribou Biosciences' positive pipeline progress with its lead allogeneic cell therapy and increased revenue under the AbbVie Agreement.
- Abbvie's (ABBV) stock went down due to investor concerns over the company's loss of patent exclusivity for its rheumatoid arthritis drug Humira, which generated 36% of the company's total revenue in 2022. However, the company has other successful drugs and is investing heavily in research and development, making it a reliable long-term investment with consistent dividend payments. Additionally, cannabis companies Green Thumb Industries and Tilray Brands appear to be in prime position for investing due to their profitability and potential for expansion.
- AbbVie (ABBV) stock went down by 1.5% last night as investors are concerned about the company's drug pipeline and the potential impact of COVID-19 on the healthcare industry.
- Neurocrine Biosciences presented data on the dissolution performance of INGREZZA capsule contents through soft foods or a gastrostomy feeding tube, which may be important for elderly patients with tardive dyskinesia, reducing the need to swallow whole capsules, but AbbVie (ABBV) stock went down by 1.5% last night.
|
| 2023-03-08 | -2.18 % |
|
| 2023-03-07 | -1.51 % |
|
| 2023-03-06 | -0.5 % |
|
| 2023-03-03 | +1.09 % |
|
| 2023-03-02 | -0.57 % |
- Abbvie (ABBV) stock went down 0.57% on March 1, as rising interest rates and deteriorating earnings estimates were cited as a big headwind for the market, despite positive purchasing managers data out of China and moderate gains in Brent and West Texas Intermediate crude.
- AbbVie (ABBV) stock was down 0.57% last night, possibly due to the publication of a new report by Visiongain which highlights how gene therapies are driving demand for the treatment of rare diseases, thus accelerating the development and approval of gene therapies, and increasing awareness campaigns by patient support groups which help to promote the benefits of treating rare diseases, leading to the demand of novel drugs among physicians.
- The article does not provide any information about AbbVie's stock going down.
- AbbVie (ABBV) stock went down -0.57% last night, but is still a solid long-term buy for both dividend and growth investors, as it generates high levels of free cash flow and is known for regularly raising dividend payouts, although there are worries surrounding replacing sales for top-selling drug Humira.
- AbbVie (ABBV) stock went down by almost 4% in the last three months, contributing to its one-year return of over 3%, along with other mega-cap stocks like Amazon, Johnson & Johnson, and Alphabet, which also dropped in the past three months.
|
| 2023-03-01 | +0.89 % |
- A dependable cash flow is a nice thing, especially for income-oriented investors. You have to pay your electric bill and rent or mortgage every month, why not get a dividend check every month too, to help pay your bills? Abbvie, Johnson & Johnson, and Medtronic are all reliable dividend payers that deliver in different months.
- On March 01, 2023, Royalty Pharma plc announced the appointment of Ashwin Pai, M.D. as Executive Vice President, Investments. This appointment signals Royalty Pharma's focus on capitalizing on the growth of the biopharmaceutical industry.
- The company is expected to report positive earnings after the market close on Wednesday.
- AbbVie is a pharmaceutical company that is going through a process of replacing revenue from a large drug with newer products. Despite the recent dip in stock prices, the company is still undervalued and payout is above average.
|
| 2023-02-28 | -0.25 % |
|
| 2023-02-27 | +1.03 % |
|
| 2023-02-24 | +0.42 % |
|
| 2023-02-23 | +0.93 % |
|
| 2023-02-22 | -0.88 % |
|
| 2023-02-17 | +1.19 % |
|
| 2023-02-16 | -1.01 % |
|
| 2023-02-15 | -1 % |
|
| 2023-02-14 | -0.74 % |
|
| 2023-02-13 | +1.1 % |
|
| 2023-02-10 | +2.25 % |
|
| 2023-02-09 | +2.83 % |
|
| 2023-02-08 | -0.37 % |
|
| 2023-02-07 | +0.08 % |
- Abbvie is a biotechnology company that is engaged in the development of small molecule drugs for the treatment of viral infections. This stock goes up when the company releases good news, such as its recent presentation on its RSV and HBV programs.
- Halozyme Therapeutics, Inc. (ABBV) is a biopharmaceutical company that is licensed to Roche, Takeda, Pfizer, AbbVie, Eli Lilly, Bristol-Myers Squibb, Alexion, argenx, Horizon Therapeutics, ViiV Healthcare and Chugai Pharmaceutical. Halozyme's proprietary ENHANZE® technology is used to facilitate the delivery of injected drugs and fluids to reduce the treatment burden for patients. This technology has been commercially validated and used in products in more than 100 global markets.
- Investors who buy shares of abbvie(ABBV) now could see their stock increase in value over time as the company continues to make smart investments with its massive cash flows.
- Investors are bullish on AbbVie because the company has a history of beating earnings estimates and its best-selling drug, Humira, lost its patent protection.
|
| 2023-02-06 | -0.12 % |
|
| 2023-02-03 | +0.25 % |
|
| 2023-02-02 | -1.2 % |
|
| 2023-02-01 | -0.78 % |
|
| 2023-01-31 | +1.44 % |
|
| 2023-01-30 | -0.43 % |
|
| 2023-01-27 | -0.76 % |
|
| 2023-01-26 | -0.26 % |
|
| 2023-01-25 | +0.07 % |
|
| 2023-01-24 | -0.58 % |
|
| 2023-01-23 | -0.7 % |
|
| 2023-01-20 | +0.59 % |
|
| 2023-01-19 | -0.33 % |
|
| 2023-01-18 | -2.38 % |
|
| 2023-01-17 | -0.5 % |
|
| 2023-01-13 | +0.91 % |
|
| 2023-01-12 | -3.15 % |
|
| 2023-01-11 | -1.55 % |
|
| 2023-01-10 | -1.25 % |
|
| 2023-01-09 | -2.94 % |
|
| 2023-01-06 | +1.87 % |
|
| 2023-01-05 | -0.12 % |
|
| 2023-01-04 | +0.81 % |
|
| 2023-01-03 | +0.48 % |
|
| 2022-12-29 | +0.2 % |
|
| 2022-12-27 | -0.07 % |
|
| 2022-12-22 | +0.65 % |
|
| 2022-12-21 | +1.02 % |
|
| 2022-12-14 | +0.04 % |
|
| 2022-12-13 | -0.32 % |
|
| 2022-12-08 | +0.36 % |
|
| 2022-12-06 | -0.13 % |
|
| 2022-12-05 | +0.17 % |
|
| 2022-12-01 | +0.28 % |
|
| 2022-11-30 | +1.88 % |
|
| 2022-11-23 | -0.25 % |
|
| 2022-11-09 | -0.61 % |
|
| 2022-11-08 | +0.29 % |
|
| 2022-11-07 | +1.94 % |
|
| 2022-11-04 | +0.6 % |
|
| 2022-11-03 | -0.07 % |
|
| 2022-10-31 | -0.82 % |
|
| 2022-10-28 | -3.84 % |
|
| 2022-10-26 | +1.8 % |
|
| 2022-10-21 | +2.89 % |
|
| 2022-10-18 | +0.13 % |
|
| 2022-10-14 | +0.01 % |
|
| 2022-10-11 | +2.31 % |
|
| 2022-10-06 | -2.12 % |
|
